Vivos Inc. Reports Earnings Results for the Full Year Ended December 31, 2022

Vivos Inc. is a radiation oncology medical device company. The Company is engaged in the development of its yttrium-90 (Y-90) based brachytherapy device, RadioGel, for the treatment of non-resectable tumors. RadioGel is a device for human therapy for non-resectable cancers in humans. It is a hydrogel liquid containing tiny Yttrium-90 phosphate microparticles that may be administered directly into a tumor. The Company’s IsoPet division is focused on bringing RadioGel yttrium-90 precision radionuclide therapy to veterinary oncologists to treat dogs, cats and horses suffering from cancerous tumors. The IsoPet solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The Company is also engaged in developing a micro-injection system for small tumor therapy for treating cancerous thyroid lymph nodes.